Member Info for chablard

Soup
Thanks for all your well informed posts, day in day out that keeps this bb level headed. Your knowledge and research is most useful (as we here sweet fa of any substance from the company).
ATB

Funny, because I can buy as many as I want.
Suggest you change your broker
ATB

Utility1
Looked back to see my last post on 6th June, and here it is copy and paste.

"All the continual talk of echo being worth a pound is either by serious rampers or just being in cloud cuckoo land .
The last thing this needs is that nonsense being spouted again here.
Echo is a small company that Hope's one day to make a profit. Not being able to service their loans speaks volumes.
Let's just see if we can become a penny share first.
Far too much hype here .
ATB"

If you think that's ramping then all I can say is you need to keep your opinions to yourself.
Have a good day

Utility1
Well thanks for your ramping post.
Very odd because up until now I've been told of for being too negative and deramping. So I very much appreciate your post that has now put me in both camps.
Quite honestly, you talk some garbage.
ATB

So did you top up on Tuesday instead, when you could have bought a million?
ATB

Interesting

Not the doctor's warning,

but that you read the Daily Mail :-)

ATB

Funny when I posted the info on VistaGen a week ago no one seemed interested. This week it's very important. Fickle lot.
ATB

Well let's hope it's biographical and not a fairy tale.
Because at the moment it's a b!@@day horror story
ATB

That's the bid dropped again.

Who sung that song, "slip sliding away "

"Not sure why they should Chab. Presumably if someone thought NFX was a strong buy at 6p its even more so now, isn’t it?"

Until tomorrow

And hopefully those that have been posting "strong buy" every day since we were in the 6p plus range will now desist in doing so .

Exactly Soup.

Regarding income, it's just a matter of waiting probably 3 or 4 weeks for a good read.
Ebbers deal payments upto, so no clear idea of payments there atm.
No point in talking about the Chinese monies.
VistaGen . Who knows.

So let's see if we are in a good financial position as stated previously by the board.

Other news over the coming months???

Random
It's nothing to do with when we got the last rns. It could have been yesterday for all I care. It's what's in the rns , and so far there has been one negative one after the other and a load of waffle.
Many have been scrambling to find something, anything, positive to say. It's all if's, but's and maybes this past year .
All the hot air about news tomorrow, news next week. Translating "over the coming months" to mean within the next couple of weeks.
Financials need to hit soon, and be very good. Anything weak or negative in them and we will be a penny share.
One must ask , who would buy NFX shares atm when they are always cheaper tomorrow.

I would like to thank Soup for his level headed factual posts these past months

ATB

You could be right Hale. I really don't know but was just a thought.
It's just that the Everinsight deal was announced after the Nfx announcement. So as it proceeded the Everinsight deal I thought it might be included.
ATB

Commercial Agreements

 We have customary clinical supply agreements and customary agreements with clinical research organizations to help us manage our nonclinical and clinical development programs. Each of our commercial agreements is non-exclusive, and we have no material contractual obligations under such agreements, except to the extent we order supplies or request services to be performed under work orders that we generate from time to time.

  

Material License Agreements
Under this heading they list two agreements, included in which is their agreement made with Everinsight, which was announced after the collaboration agreement with Nuformix. The only reason I can see for this is their agreement with Nuformix is loose and any payments unspecified. If there was any form of regular payments to us it would have to have been disclosed in VistaGen's very long and detailed annual report.

VistaGen annual report out. Lot going on

ATB

Interprete her words as you wish , but when she says there is nothing new to announce and looking forward they will rns the financials in July, I take to mean exactly that.
And your final paragraph mentioning lack of information regarding detail on collaboration agreements rather sums up how little we are told as shareholders imo.
ATB

Nervous times. Sp looking rather fragile atm, and can see, after Fleurs words, that there will be an absence of anything substantial before financials.
Would expect then to hear in detail the commercial implications regarding the tie up with VistaGen.
Starting to get rather tedious second guessing it's current state.
ATB

Extracts fro Fleur email to Willowman

"since the release of our Busines Update in May
2020, there is nothing more to update the market on.

Looking ahead; in July, we will be announcing Preliminary Results for the
period year ended 31 March 2020, and a date will be set for this and
communicated in due course. "

Note , nothing more to update the market on.......
So next rns to be financials at end of July imo.

" 

On June 24, 2020, VistaGen Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “License Agreement”) with EverInsight Therapeutics Inc., a company incorporated under the laws of the British Virgin Islands (“EverInsight”), pursuant to which the Company granted EverInsight an exclusive license to develop and commercialize PH94B, the Company’s novel, rapid-onset neurosteroid drug candidate for multiple anxiety-related disorders, in Greater China (which includes Mainland China, Hong Kong, Macau and Taiwan), South Korea and Southeast Asia (which includes Indonesia, Malaysia, Philippines, Thailand and Vietnam) (collectively, the “Territory”). The Company retains development and commercialization rights for PH94B in the rest of the world.

 

Under the terms of the License Agreement, the Company is entitled to receive an upfront payment of $5.0 million. The Company may also receive up to an additional $172 million in milestone payments upon EverInsight’s achievement of certain developmental, regulatory and sales milestone events related to PH94B. The Company is also entitled to receive certain royalties on net sales, if any, of PH94B in the Territory following receipt of any required regulatory approval. In addition, EverInsight has the right to sublicense to affiliates and third parties in the Territory."

ATB